PEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Penumbra Inc. (PEN) is not a strong buy at the moment for a beginner investor with a long-term focus and $50,000-$100,000 available. While the company has shown solid financial growth in Q4 2025 and has positive analyst sentiment, the lack of strong technical or proprietary trading signals, coupled with neutral trading sentiment, suggests waiting for a clearer entry point.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 58.544, and moving averages are converging, showing no clear trend. The stock is trading near its pivot point of 340.034, with resistance at 341.569 and support at 338.498, suggesting limited immediate upside.
Penumbra's Q4 2025 financial performance showed significant growth, with revenue up 22.1% YoY and net income up 40.55% YoY. Analysts have raised price targets, with some citing strong U.S. Embo growth and sector recovery. The company is positioned for long-term growth with innovative products and expanding market share.
The pending acquisition by Boston Scientific has led to analyst downgrades, and Thunderbolt approval delays have raised concerns. Technical indicators do not show a strong upward trend, and options data suggests a slightly bearish sentiment with a Put-Call ratio above 1.
In Q4 2025, Penumbra reported revenue of $385.38 million, up 22.1% YoY, and net income of $47.34 million, up 40.55% YoY. EPS increased by 46.34% to 1.2, and gross margin improved to 68.02%, up 1.84% YoY. These figures indicate strong financial growth and operational efficiency.
Analysts are generally positive on Penumbra, with multiple price target increases and Outperform ratings. However, recent downgrades from Truist and Baird due to the Boston Scientific acquisition reflect mixed sentiment. The average price target is around $360-$374, suggesting limited upside from the current pre-market price of $339.9.
